Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
| 1. | On the Payment Date, the Company will withhold 25% of the Nasdaq Dividend amount and remit the tax to the Tax Agent, who will handle it in accordance with the Ruling's terms and conditions. | |
| 2. | The remaining 75% of the Nasdaq Dividend will be sent by the Company to its U.S. transfer agent, Equiniti Trust Company, LLC, which will distribute the amount to the Nasdaq Shareholders, including through brokers holding the Company's shares in brokerage accounts on behalf of Nasdaq Shareholders. | |
| 3. | Nasdaq Shareholders who declare residency in a Treaty State and the sole beneficial ownership of the Nasdaq Dividend may apply to the Tax Agent to receive (subject to meeting documentation and other requirements) the difference between the 25% tax remitted to the Tax Agent and the withholding tax rate specified in the applicable tax treaty. Applications must be received by the Tax Agent between the Payment Date and the close of business on January 11, 2027, together with all relevant documentation, as follows: | |
| (i) | Bank account details, applicable identification document, and confirmation of residence for 2026 issued by the taxing authority of the shareholder's state of tax residence; | |
| (ii) | A written declaration under which the Nasdaq Shareholder declares that: (a) it is not an Israeli resident for tax purposes for 2026; (b) it does not hold more than 5% of the Company's issued share capital and its Dividend income does not exceed $500,000; (c) it acquired the shares on or after the listing of the Company's shares on Nasdaq and while the shares were listed for trading, and it was not an Israeli resident for tax purposes when it acquired the shares; (d) in the case of an individual or a corporation, it is the sole beneficial owner of the Dividend; and (e) in the case of an entity, that more than 75% of its shareholders/partners/beneficiaries (as applicable), directly or indirectly, are individuals who are residents of its state of residence for 2026; | |
| (iii) | Non-Israeli corporate Nasdaq Shareholders must also provide the share register of their shareholders or partners as of the Record Date (in the case of a corporation or partnership) or a list of beneficiaries, settlors and trustees as of the Record Date (in the case of a trust); and | |
| (iv) | Such additional documents as requested by the Tax Agent to establish tax residence or entitlement to a Reduced Withholding Tax Rate. | |
| 4. | Israeli corporate Nasdaq Shareholders entitled to an exemption from Israeli withholding tax must provide the Tax Agent, by the close of business on January 11, 2027, a valid ITA certificate of exemption from withholding tax and a copy of their certificate of incorporation. | |
| 5. | No refund of excess withholding tax will be made by the Tax Agent for Nasdaq Shareholders holding more than 5% of the Company's issued share capital or entitled to Dividend amounts exceeding $500,000, except in accordance with a valid ITA approval. | |
| 6. | The Tax Agent will transfer withheld amounts to the ITA, excluding those amounts returned to Nasdaq Shareholders, and will return withheld amounts to Nasdaq Shareholders' accounts within 30 days of payment to the ITA, subject to receipt of the required documentation. | |
| 7. | The Ruling addresses only withholding tax procedures and does not determine the actual tax liability of any Nasdaq Shareholder with respect to the Nasdaq Dividend or otherwise. | |
Tax Agent Contact Information
IBI Trust Management
Tel No: +972-3-5193896, +972 506 209 410
Email:...
We encourage you to contact the Tax Agent, at the contact details provided above, if you need any clarifications in completing the forms required under the Ruling to obtain a Reduced Withholding Tax Rate or if you have any questions concerning the process. If you are unable to access the forms via the link below, hard copies of the forms can be obtained free of charge by email, by contacting the Tax Agent at the contact details provided above.
Please note that the Tax Agent will not provide any tax advice to any shareholder, including any Nasdaq Shareholder. Shareholders should consult their own tax and financial advisors.
In order to be eligible to benefit from a Reduced Withholding Tax Rate, Nasdaq Shareholders must provide the Tax Agent with all documentation required under the Ruling no later than January 11, 2027.
If a Nasdaq Shareholder fails to provide the Tax Agent with all the documentation required by January 11, 2027, the Tax Agent will not be able to process that Nasdaq Shareholder's application and will not be able to return any amounts originally remitted on behalf of such Nasdaq Shareholder nor provide any confirmation of tax withholding to such Nasdaq Shareholder, whether in connection with the Ruling or any other tax filing by such Nasdaq Shareholder.
Link to forms:
About Kamada
Kamada Ltd. (the“Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company's strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties' pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company's marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: (1) the expected timing of the dividend payment on December 9, 2026, and (2) the potential eligibility of certain shareholders for a Reduced Withholding Tax Rate on their share of the Nasdaq Dividend, subject to compliance with the terms and conditions of the Ruling, as extended by the Israel Tax Authority. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East, and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the potential effect of imposed tariffs on overall international trade and specifically on Kamada's ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada's ability to leverage new business opportunities and integrate them with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, Kamada's ability and board discretion to declare and pay annual cash dividends, and other risks detailed in Kamada's filings with the U.S. Securities and Exchange Commission (the“SEC”), including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file with, or furnished to, the SEC and available on the SEC's website at The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACTS:
Chaime Orlev
Chief Financial Officer
...
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment